FACTS AND FIGURES

JSC «Grindeks» is the leading pharmaceutical company in the Baltic States.
Since 2nd of January 2006 shares of «Grindeks» are listed in the Official list of "NASDAQ OMX Riga".

STRUCTURE OF CONCERN
4 subsidiaries:
• JSC "Tallinn Pharmaceutical Plant"
• JSC "Kalceks"
• "«Grindeks» Rus" Ltd.
• "Namu apsaimniekošanas projekti" Ltd.
Branches in:
Estonia, Lithuania
Representative offices in:
Russia, Ukraine, Belarus, Moldova, Kazakhstan, Georgia, Azerbaijan, Uzbekistan, Armenia

AREAS OF BUSINESS
Research, development, manufacturing and sales of:
• brand products;
• generic products;
• active pharmaceutical ingredients (APIs).  

PRODUCTS
• Brand products– Mildronate® and Ftorafur®
• More than 100 final dosage forms – «Grindeks» specializes in the heart and cardiovascular, psychotropic and anti-cancer therapeuctic groups of medications 
• 22 different APIs

PRODUCTION
• APIs and final dosage forms (tablets, capsules and syrups) are produced in «Grindeks» in Riga, Latvia
• ointments are produced "Tallinn pharmaceutical plant" in Estonia
• injections are produced under the contract manufacturing agreements in pharmaceutical company "Sanitas" AB in Lithuania, pharmaceutical company "Jelfa" SA in Poland and pharmaceutical company "HBM Pharma" s.r.o. in Slovakia

MAIN FINANCIAL INDICATORS OF 2012
• turnover  117.7 million euro 
• net profit 13.6 million euro 
• gross profit 72.2 million euro 

MARKETS
• «Grindeks» production is exported to 55 countries
• Exports represent 95% of total sales amount
• Main markets for final dosage forms – Baltic States, Russia and other CIS countries.
• Main export markets of APIs – Russia, Germany, the Netherlands, the USA, Japan.